X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

The Supreme Court on Monday declined to consider a patent dispute between biotech drug maker Amgen Inc. and two other companies involving Amgen’s blockbuster anemia drug Epogen.

Despite passing on this case, justices have shown a heightened interest in patent law recently, taking up a half-dozen cases in the past two years and issuing two high-profile decisions in April.

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 1 article* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?

 
Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.

 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.